SCHEMBL756436

SCHEMBL756436

Cc1nc(NC(=O)CC#N)cc(-c2c(Nc3ccn(C)n3)nc3ccccn23)n1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTOR P42345 9/20 0.76
PIK3CA P42336 8/20 0.76
TDP1 Q9NUW8 1/20 0.37
CSNK1D P48730 3/20 0.37
CSNK1E P49674 3/20 0.37
NOTUM Q6P988 1/20 0.36
AGPAT2 O15120 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ABL1 P00519 1/20 0.35
USP7 Q93009 1/20 0.35
JAK1 P23458 1/20 0.34
JAK3 P52333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2789558 0.87 MTOR (0.77) MTORPIK3CAMKNK1ABL1JAK1
SCHEMBL2787610 0.87 MTOR (1.00) MTORPIK3CACSNK1DCSNK1ELMNA
SCHEMBL11029468 0.86 MTOR (0.76) MTORPIK3CACSNK1DCSNK1ENOTUM
SCHEMBL761701 0.84 MTOR (0.62) MTORPIK3CACSNK1DCSNK1EMKNK1
SCHEMBL755854 0.83 MTOR (0.71) MTORPIK3CACSNK1DCSNK1EMKNK1
SCHEMBL752642 0.82 MTOR (0.69) MTORPIK3CAALDH1A1LMNA
SCHEMBL751580 0.78 MTOR (0.71) MTORPIK3CAUSP7
Trifluoroacetic Acid SCHEMBL754788 0.78 MTOR (0.62) MTORPIK3CACSNK1DALDH1A1LMNA
SCHEMBL755585 0.75 MTOR (0.81) MTORPIK3CANOTUMKDM4EALDH1A1
SCHEMBL757042 0.74 MTOR (0.78) MTORPIK3CANOTUMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD MTOR 21/4885PIK3CA 1/4885TDP1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.